
BMRA
Biomerica Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.200
Open
3.070
VWAP
3.05
Vol
25.78K
Mkt Cap
7.67M
Low
3.000
Amount
78.62K
EV/EBITDA(TTM)
--
Total Shares
16.82M
EV
4.61M
EV/OCF(TTM)
--
P/S(TTM)
1.16
Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
Show More
1 Analyst Rating

-0.37% Downside
Wall Street analysts forecast BMRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRA is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold

-0.37% Downside
Current: 3.011

Low
3.00
Averages
3.00
High
3.00

-0.37% Downside
Current: 3.011

Low
3.00
Averages
3.00
High
3.00
The End
See All Ratings

No Data
Valuation Metrics
The current forward P/E ratio for Biomerica Inc (BMRA.O) is 0.97, compared to its 5-year average forward P/E of 9.25. For a more detailed relative valuation and DCF analysis to assess Biomerica Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
9.25
Current PE
0.97
Overvalued PE
43.55
Undervalued PE
-25.04
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
3.34
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
14.05
Undervalued EV/EBITDA
-7.38
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued
5Y Average PS
3.05
Current PS
0.30
Overvalued PS
5.70
Undervalued PS
0.40
Financials
Annual
Quarterly
FY2025Q3
YoY :
+10.03%
1.12M
Total Revenue
FY2025Q3
YoY :
-39.50%
-1.21M
Operating Profit
FY2025Q3
YoY :
-39.36%
-1.16M
Net Income after Tax
FY2025Q3
YoY :
-47.25%
-0.48
EPS - Diluted
FY2025Q3
YoY :
-42.27%
-1.05M
Free Cash Flow
FY2025Q3
YoY :
-111.60%
1.70
Gross Profit Margin - %
FY2025Q3
YoY :
-24.22%
-75.47
FCF Margin - %
FY2025Q3
YoY :
-44.89%
-103.93
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BMRA News & Events
Events Timeline
2025-07-02 (ET)
2025-07-02
08:11:50
Biomerica announces inFoods IBS received CPT PLA code

2025-06-26 (ET)
2025-06-26
08:26:19
Biomerica announces appointment of Madel as Chief Commercial Officer

2025-06-05 (ET)
2025-06-05
08:23:15
Biomerica announces publication of data from inFoods IBS clinical study

Sign Up For More Events
Sign Up For More Events
News
9.0
07-02NASDAQ.COMBiomerica Secures PLA Code For InFoods IBS Test, Advancing Reimbursement Access
5.0
06-26NewsfilterClinical Diagnostics Industry Leader Scott Madel Joins Biomerica's Team as Chief Commercial Officer
5.0
06-06NewsfilterBiomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair
Sign Up For More News
People Also Watch
FAQ

What is Biomerica Inc (BMRA) stock price today?
The current price of BMRA is 3.011 USD — it has decreased -3.18 % in the last trading day.

What is Biomerica Inc (BMRA)'s business?

What is the price predicton of BMRA Stock?

What is Biomerica Inc (BMRA)'s revenue for the last quarter?

What is Biomerica Inc (BMRA)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Biomerica Inc (BMRA)'s fundamentals?

How many employees does Biomerica Inc (BMRA). have?
